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N
arrowing of the lumen of the renal artery is
termed renal artery stenosis (RAS) and can
be a cause of hypertension and chronic
kidney disease (CKD).1 When hypertension is
caused by RAS the term renovascular hypertension
is used, but the only way to be certain of the
diagnosis is to demonstrate that relief of the renal
artery narrowing results in a return to a normal
blood pressure. This is because essential hyperten-
sion is considerably more common than, and a risk
factor for, RAS so the coexistence of RAS and
hypertension in a patient does not infer causality.
In addition, even where clinically significant RAS
is the initial cause of hypertension, reversal of the
stenosis may not result in a normal blood pressure
or renal function if longstanding hypertension has
produced irreversible contralateral renal injury.2
RAS is most commonly due to atherosclerotic
renal artery stenosis (ARAS) and has been reported
to be present in around 30% of patients having
routine coronary angiography and up to 50% of
patients undergoing peripheral angiography.2 The
presence and anatomical location of RAS can be
confirmed by non-invasive imaging with duplex
ultrasound, computed tomographic or magnetic
resonance angiography or by invasive imaging with
catheter-based angiography.2 Isotope renography
combined with administration of the ACE inhibitor
captopril can be used to assess the functional severity
of the stenosis, and comparison of the renin activity
in the two renal veins is sometimes useful to confirm
the diagnosis.2 However, none of these investigations
can reliably indicate which patients will respond to
percutaneous or surgical intervention and which are
best managed with antihypertensive drugs.
The medical management of ARAS centres on
effective blood pressure control, lipid-lowering
treatment, smoking cessation and antiplatelet
treatment.1 2 Restoration of near-normal blood
flow to the kidney by angioplasty or surgery
(revascularisation) holds an intuitive appeal, but
a recent systematic review found no clear evidence
to suggest that revascularisation was better than
medical treatment.3 There may be modest improve-
ments in hypertension control but cure of hyper-
tension is unlikely, and no firm conclusions can be
drawn about the impact of renal artery revascular-
isation on the development of ischaemic heart
disease, stroke and death.3 4 In contrast, medical
management of hypertension is well established
and has a large evidence base.5 Also, there is no
good evidence to support an improvement in
kidney function after renal artery revascularisa-
tion.3 On the other hand, angioplasty can produce
serious complications such as renal artery
occlusion and cholesterol embolisation2 and, with
a lack of robust evidence demonstrating benefit, its
role is still unclear.
With this management uncertainty as a back-
ground, the American College of Cardiology and the
American Heart Association (ACC/AHA) recently
produced guidelines for when renal arteriography
should be performed at the time of coronary
arteriography (so called ‘‘drive-by’’ renal arteriogra-
phy).6 These brief drive-by arteriography guidelines
are based on the considerably more substantial
guidelines for the management of peripheral vascu-
lar disease (including ARAS)7 and state that it is
reasonable to screen for ARAS in at-risk patients who
are candidates for revascularisation.6 The definitions of
at-risk patients and recommendations for revascu-
larisation are presented in table 1.
Within the guidelines the following is suggested:
‘‘Percutaneous revascularisation is reasonable for
patients with haemodynamically significant RAS
and unstable angina’’. Haemodynamically signifi-
cant renal artery stenosis is defined as (a) a 50–70%
diameter stenosis by visual estimation with a peak
translesional gradient (measured with a 5F or
smaller catheter or pressure wire) of at least
20 mm Hg or a mean gradient of at least 10 mm
Hg; (b) any stenosis of at least 70% diameter; or (c)
>70% diameter stenosis by intravascular ultrasound
measurement.7 The authors acknowledge that this
guidance for patients with unstable angina is based
on small case series of selected patients because
larger, more robust, studies have yet to be performed.
Given that unstable angina is a common indication
for coronary arteriography, a large number of
patients will also be candidates for renal artery
imaging. This is in addition to the significant number
of patients who will be candidates for renal artery
imaging based on a history of hypertension or CKD.
In America, percutaneous renal artery revascularisa-
tion is increasingly being performed by cardiologists,8
so a by-product of increased renovascular imaging is
likely to be an increase in renal artery revascularisa-
tion at the time of coronary arteriography. In the UK
fewer cardiologists routinely perform renal artery
angioplasty at present. However, because coronary
angioplasty requires similar skills there is consider-
able potential for the number of renal artery
revascularisation procedures to increase.
The new ACC/AHA guidelines for when renal
arteriography should be performed in patients
undergoing coronary arteriography amount to the
introduction of a new and unproved screening
Abbreviations: ACC/AHA, American College of
Cardiology and the American Heart Association; ARAS,
atherosclerotic renal artery stenosis; CKD, chronic kidney
disease; RAS, renal artery stenosis
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programme. However, the guidelines fail to meet the screening
criteria adopted by the World Health Organisation9 (box 1)
because haemodynamically significant ARAS will be diagnosed
without a strong evidence base for management. We would
strongly discourage renal artery revascularisation at the time of
coronary arteriography until a considerably more robust
evidence base is available.
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Box 1 Criteria for a screening programme
N Is the disease an important public health problem?
N Is there an effective treatment for localised disease?
N Are facilities for further diagnosis and treatment available?
N Is there an identifiable latent or early symptomatic stage
of disease?
N Is the technique to be used for screening effective?
N Are the tests acceptable to the population?
N Is the natural history of the disease known?
N Is there a strategy for determining which patients should
and should not be treated?
N Is the cost of screening acceptable?
N Is effective treatment available and does management of
cases in the early stages have a favourable impact on
prognosis?
Commentary: Shoot the renals!
F C Luft, C M Gross
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Atherosclerotic renal artery stenosis (ARAS) is a growing
dilemma. The condition is increasingly common and can
promulgate hypertension and result in renal failure. However,
patients with ARAS generally die owing to their coronaries or
cerebral vessels. Intervention, by stenting or angioplasty is
beloved and believed, but not proved. The American Heart
Association has recently published guidelines regarding
patients at high risk for ARAS who are potential candidates
for revascularisation. Since this phraseology includes practi-
cally every patient with atherosclerosis, these guidelines appear
ill advised.
I
n this issue of Heart, Dear, Padfield and Webb1 take umbrage
at recent (2006) recommendations published by the
American Heart Association (AHA) regarding new guidelines
for ‘‘drive-by’’ renal arteriography during interventions for
atherosclerotic lesions elsewhere in the body.2 This Practice
Guideline was followed by a multispecialty consensus docu-
ment stating basically the same thing.3 The multispecialty
pundits concluded that renal angiography should be
‘‘selectively applied to patients at high risk for atherosclerotic
renal artery stenosis (ARAS) who are potential candidates for
revascularisation’’. Dear et al draw attention to the fact that the
guidelines recommend screening for ARAS in all patients at risk
who are candidates for revascularisation.1 ‘‘At risk’’ was defined
according to hypertension, age of onset, accelerated course,
kidney size discrepancy, ‘‘flash’’ pulmonary oedema, worsening
renal function and multivessel atherosclerosis elsewhere. Since
the ‘‘unstentable’’ patient is yet to be encountered, Dear et al
suggest that the number of patients subjected to renal artery
stenting is bound to increase. They point out that the AHA
recommends a generalised ‘‘screening programme’’ for an
entity that has no sound basis for management. A recent
meta-analysis by Balk et al underlines their view.4 Have Dear et
al indeed caught old Auntie AHA with her pantaloons at half
mast?
The issues are complex. ARAS is a moving target in an ever-
aging, ever-more diabetic population. Furthermore, the options
Abbreviations: AHA, American Heart Association; ARAS, atherosclerotic
renal artery stenosis; CORAL, Cardiovascular Outcomes in Renal
Atherosclerotic Lesions
www.heartjnl.com
